. Author manuscript; available in PMC: 2015 Apr 9.

Published in final edited form as: Curr HIV Res. 2012 Jan 1;10(1):9–18. doi: 10.2174/157016212799304625

Table 3.

Zinc Acetate (ZA)-Containing Gels Provide 24h of Significant Protection Against SHIV-RT Infection

Gel	Time of Virus Challenge After the Last Gel (Infected/Challenged)			Total (Infected/Challenged)	Protection vs Carrageenan	P Value vs Carrageenan
Gel	4h	8h	24h	Total (Infected/Challenged)	Protection vs Carrageenan	P Value vs Carrageenan
MIV-150/ZA	0/7	0/7	2/14^*	2/28	89%	<0.0002
ZA	ND	1/7	3/14^*	4/21	70%	<0.012
MIV-150	ND	2/7	4/7	6/14	33%	<0.5
Carrageenan				9/14^{^}

Data from animals receiving a daily dosing of gel for 2 weeks and dosing every other day for 4 weeks has been pooled.

^{^}

Data from real time controls for each challenge are pooled with data from historical controls.

Depo-Provera-treated Chinese rhesus macaques were challenged with 10³ TCID₅₀ SHIV-RT at the indicated times relative to repeated gel application. This virus dose routinely infects 60–65% of placebo/untreated animals.

ND = not done.

From reference [138].